GL1X · GenesisL1 explorer

MolNFT v2 · #51075 · protein

Selective and Dual Action Orally Active Inhibitors of Thrombin and Factor Xa

2UWL · Coagulation factor X: “Selective and Dual Action Orally Active Inhibitors of Thrombin and Factor Xa”. X-ray diffraction at 1.9, 1 ligand (895), 2 pockets (best druggability 0.47). MolNFT v2 #51075 on GenesisL1: 3D structure, binding…

PDB
2UWL
Type
protein
Length
286 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v2 / PDB Bank
Contract
0xd58B01f6C18086e5202cdC5D7Ad3E41790360102
Owner
0xF4e1AA6f26B7DA48EeAD9B24a97927303eeA07b8
Resolution
1.9
Source
HOMO SAPIENS
Molecule
Coagulation factor X
EC
3.4.21.6
UniProt
P00742
Ligands
895
Pockets
2 · best druggability 0.47

Structure

x-ray diffraction · resolution 1.9 · 2 distinct chains · 14% helix, 36% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACoagulation factor X (EC 3.4.21.6)protein23414% helix, 37% strandP00742
BCoagulation factor X (EC 3.4.21.6)protein5213% helix, 31% strandP00742

Ligands and binding sites

  • 895 · 2-(5-chloro-2-thienyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11660.470.7626empty
21120.440.7824895

Interfaces

1 interface between chains.

  • A–B · 862 Ų buried · 9 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 8 disulfide (disulfide).

Compared structures

  • 2UWL · Selective and dual action orally active inhibitors of thrombin and factor xa · the same entry in another collection · chain A against A, TM-score 1.00
  • P00742 · AlphaFold monomer V2.0 prediction for coagulation factor X (P00742) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.